Toxic cholesterol cleared via urine in trial

Cyclarity Therapeutics is testing a compound called UDP-003. It targets a substance known as 7-ketocholesterol (7KC), an oxidized form of cholesterol that accumulates inside foam cells (macrophages that have absorbed too much fat in artery walls). Those foam cells are an early feature of atherosclerosis, or hardening of the arteries.

In a Phase 1 trial conducted at Monash University in Australia, healthy volunteers received UDP-003 by infusion. The researchers then measured 7KC levels in urine and found the compound was actively excreted. This is the first time that has been demonstrated clinically in humans.

A different angle on artery disease

Standard treatments for atherosclerosis focus on lowering LDL cholesterol or suppressing inflammation. UDP-003 aims to remove a specific toxic substance rather than manage systemic risk factors. If foam cells shed their 7KC load, they may recover their normal function as tissue-clearing repair cells.

This was a Phase 1 study in healthy people. It was designed to test safety and basic mechanism, not to show clinical benefit in patients with heart disease. Whether UDP-003 can actually shrink plaques or prevent cardiovascular events remains an open question.

What still needs to happen

Urinary excretion of 7KC is a proxy marker. It shows the substance is leaving the body, but not yet whether that is enough to reverse disease or reduce mortality. Larger trials with patients are needed.

Still, many compounds fail to show any measurable effect in early clinical testing. UDP-003 did what its developers predicted. For the longevity field, where cardiovascular aging remains one of the largest contributors to disease burden and early death, that distinction matters.

Read the original article